Detalhe da pesquisa
1.
Exacerbation of Background Nuclear Cataracts in Sprague-Dawley Rats in Embryo-Fetal Development Studies With JNJ-42165279, a Fatty Acid Amide Hydrolase Inhibitor.
Toxicol Pathol
; 49(6): 1193-1205, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34128434
2.
Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia.
J Pharmacol Exp Ther
; 354(3): 471-82, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26177655
3.
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
Cancer Cell
; 6(5): 507-16, 2004 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-15542434
4.
Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directions.
Toxicol Pathol
; 38(7): 1138-66, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20926828
5.
Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793.
ACS Med Chem Lett
; 11(10): 2002-2009, 2020 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33062185
6.
Novel benzamide-based histamine h3 receptor antagonists: the identification of two candidates for clinical development.
ACS Med Chem Lett
; 6(4): 450-4, 2015 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25893048
7.
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.
Mol Cancer Ther
; 9(10): 2641-51, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20937592